Intellia Therapeutics, Inc. (NTLA)

Market Cap	2.00B
Revenue (ttm)	36.28M
Net Income (ttm)	-481.19M
Shares Out	96.44M
EPS (ttm)	-5.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	994,220
Open	20.10
Previous Close	20.02
Day's Range	19.37 - 20.99
52-Week Range	19.37 - 47.48
Beta	1.80
Analysts	Buy
Price Target	67.64 (+225.82%)
Earnings Date	May 10, 2024

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 526
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA

Financial Performance

In 2023, NTLA's revenue was $36.28 million, a decrease of -30.40% compared to the previous year's $52.12 million. Losses were -$481.19 million, 1.48% more than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $67.64, which is an increase of 225.82% from the latest price.

Price Target

$67.64

(225.82% upside)

Analyst Consensus: Buy